ClinicalTrials.gg
CompletedNCT00849433Updated Jan 16, 2015

Effects of Smoking on Bronchial Epithelium

An observational study in Asthma and Copd, sponsored by University Medical Center Groningen. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by University Medical Center Groningen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory airway diseases affecting millions of people worldwide. Inhaled corticosteroids (ICS) are by far the most effective treatment with a broad anti-inflammatory spectrum. Nevertheless, most COPD patients and a proportion of severe asthma patients are corticosteroid-resistant (CR) and to fail to respond to ICS even when higher doses are given. These corticosteroid-resistant patients suffer from persistent symptoms and repeated asthma exacerbations. It has been suggested that smoking and oxidative stress may induce corticosteroid-resistance. The reactive oxygen species (ROS) responsible for oxidative stress can be generated exogenously (air pollutants, cigarette smoke) and endogenously by metabolic reactions. After inhaling air pollutants or cigarette smoke, the bronchial epithelium is exposed. Preliminary data from our own lab suggest that smoking and oxidative stress may decrease epithelial cell-cell contact formation. This results not only in a decreased barrier function, but also in an increased production of pro-inflammatory mediators.

02

Conditions studied

  • Asthma
  • Copd

Keywords

  • Inflammation
  • epithelial
  • integrity
  • ECIS
03

In context

Asthma

4,010 studies on the registry are indexed under Asthma; 514 are open to participants now.

This study's planned enrollment of 60 is below the median of 150 across 993 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 625 studies on the registry; 174 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

30 patients with asthma; 30 patients with COPD

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for patients with allergic asthma:

  • Age between 18 and 65 years.
  • \< 10 packyears, no smoking in the last year.
  • The presence of allergy defined as at least one positive wheal/flare reaction (2 mm relative to control) to a skin prick test with sixteen common aero-allergens).
  • FEV1 > 80% predicted.
  • PC20 methacholine or PC20 histamine \< 8 mg/ml.

Inclusion criteria for patients with COPD:

  • Age between 45-75 years.
  • ≥ 10 packyears.
  • FEV1 between 30% and 80% of predicted.

Exclusion criteria:

  • Any disease that, as judged by the Investigator, could have affected the outcome of this study.
  • A respiratory tract infection within 4 weeks of the start of the study.
  • A history of life-threatening asthma, defined as exacerbation of asthma or COPD that required intubation or was associated with hypercapnea.
  • History of myocardial infarction or documented myocardial ischemia.
  • Pregnancy, or the possibility of being pregnant (a pregnancy test will be performed in women of childbearing potential who do not use adequate anticonception as judged by the investigator).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1

    30 patients with asthma

  • 2

    30 patients with COPD

06

What researchers measure

Primary outcomes

  1. Epithelial integrity as measured with ECIS

    Time frame: 2 years

Secondary outcomes

  1. Inflammatory cells and mediators

    Time frame: 2 years

  2. Production of inflammatory cytokines

    Time frame: 2 years

  3. Markers of epithelial integrity

    Time frame: 2 years

07

Study locations

1 site
  • University Medical Centre Groningen
    Groningen, Provincie Groningen 9713 GZ, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00849433
Responsible party
Maarten van den Berge (doctor, University Medical Center Groningen) — Principal investigator
First posted
Feb 23, 2009
Start date
Apr 2009
Primary completion
Apr 2012
Completion
Apr 2013
Last update
Jan 16, 2015

Study contacts

Maarten van den Berge, MD, PhD
principal investigator · University Medical Center Groningen
Dirkje S Postma, Professor
study director · University Medical Center Groningen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion